MXPA03001338A - Particulas quimericas 11bc inmunogenicas con mayor estabilidad. - Google Patents
Particulas quimericas 11bc inmunogenicas con mayor estabilidad.Info
- Publication number
- MXPA03001338A MXPA03001338A MXPA03001338A MXPA03001338A MXPA03001338A MX PA03001338 A MXPA03001338 A MX PA03001338A MX PA03001338 A MXPA03001338 A MX PA03001338A MX PA03001338 A MXPA03001338 A MX PA03001338A MX PA03001338 A MXPA03001338 A MX PA03001338A
- Authority
- MX
- Mexico
- Prior art keywords
- enhanced stability
- hbc chimer
- chimer particles
- immunogenic
- immunogenic hbc
- Prior art date
Links
- 241000251204 Chimaeridae Species 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 239000002245 particle Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22584300P | 2000-08-16 | 2000-08-16 | |
US22686700P | 2000-08-22 | 2000-08-22 | |
US09/930,915 US20030138769A1 (en) | 2000-08-16 | 2001-08-15 | Immunogenic HBc chimer particles having enhanced stability |
PCT/US2001/041759 WO2002014478A2 (en) | 2000-08-16 | 2001-08-16 | IMMUNOGENIC HBc CHIMER PARTICLES HAVING ENHANCED STABILITY |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03001338A true MXPA03001338A (es) | 2004-01-26 |
Family
ID=27397530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03001338A MXPA03001338A (es) | 2000-08-16 | 2001-08-16 | Particulas quimericas 11bc inmunogenicas con mayor estabilidad. |
Country Status (12)
Country | Link |
---|---|
US (3) | US20030138769A1 (es) |
EP (1) | EP1333857A4 (es) |
JP (2) | JP2005517380A (es) |
KR (1) | KR20030084887A (es) |
AP (1) | AP2003002752A0 (es) |
AU (2) | AU2001285452B2 (es) |
BR (1) | BR0113307A (es) |
CA (1) | CA2420037A1 (es) |
EA (1) | EA006207B1 (es) |
MX (1) | MXPA03001338A (es) |
OA (1) | OA12366A (es) |
WO (1) | WO2002014478A2 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6942866B2 (en) | 2000-08-16 | 2005-09-13 | Apovia, Inc. | Malaria immunogen and vaccine |
US7022830B2 (en) * | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
EP1450856B1 (en) | 2001-09-14 | 2009-11-11 | Cytos Biotechnology AG | Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
MXPA04002644A (es) | 2001-10-05 | 2004-07-08 | Cytos Biotechnology Ag | Conjugados que portan un peptido de angiotensina y usos de los mismos. |
AT410666B (de) * | 2001-12-11 | 2003-06-25 | Intercell Biomedizinische Forschungs & Entwicklungs Gmbh | Nukleinsäure bindende peptide und die verwendung derartiger peptide in pharmazeutischen präparaten |
AU2003213168A1 (en) * | 2002-02-21 | 2003-12-19 | Apovia, Inc. | IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE |
US7351413B2 (en) * | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
NZ537003A (en) | 2002-07-18 | 2008-03-28 | Cytos Biotechnology Ag | Hapten-carrier conjugates comprising virus like particles and uses thereof |
WO2004016282A1 (en) | 2002-07-19 | 2004-02-26 | Cytos Biotechnology Ag | Vaccine compositions containing amyloid beta1-6 antigen arrays |
AU2003300841B2 (en) * | 2002-12-10 | 2008-03-20 | Lorantis Ltd. | Stabilized immunogenic HBc chimer particles |
WO2004084940A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
US7144712B2 (en) * | 2003-07-30 | 2006-12-05 | Vaccine Research Institute Of San Diego | Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
AU2004260665B2 (en) * | 2003-07-30 | 2007-11-15 | Vlp Biotech, Inc. | Hepatitis virus core proteins as vaccine platforms and methods of use thereof |
US7320795B2 (en) * | 2003-07-30 | 2008-01-22 | Vaccine Research Institute Of San Diego | Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
US7408075B1 (en) * | 2005-03-23 | 2008-08-05 | The United States Of America As Represented By The Department Of Health And Human Services | Synthesis of phosphocholine ester derivatives and conjugates thereof |
US20070160628A1 (en) * | 2005-08-31 | 2007-07-12 | Birkett Ashley J | Stabilized virus-like particles and epitope display systems |
BRPI0714721A2 (pt) | 2006-07-14 | 2013-04-24 | Sanofi Pasteur Biologics Co | construÇço de vacinas de vÍrus recombinante por inserÇço direta mediada por transpàson de determinantes imunolàgicos estranhos em proteÍnas de vÍrus vetorial |
EP1897887A1 (de) * | 2006-09-08 | 2008-03-12 | Universitätsklinikum Freiburg | Split-Core-Partikel für die Präsentation von Fremdmolekülen, insbesondere für Impfstoffanwendungen und Verfahren zu deren Herstellung |
WO2008100290A2 (en) | 2006-09-29 | 2008-08-21 | Sanofi Pasteur Biologics Co | Recombinant rhinovirus vectors |
KR20090092764A (ko) | 2006-09-29 | 2009-09-01 | 사노피 파스테르 바이오로직스 씨오 | 신규한 리노바이러스 중화 면역원 및 이의 백신 용도로의 이용 |
EP1920781B1 (en) * | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors |
KR100861923B1 (ko) * | 2006-12-07 | 2008-10-09 | 메디칸(주) | 바이러스 항원 발현 재조합 벡터로 형질전환된 곤충세포를 이용한 a형 간염 바이러스 항원의 제조방법 |
WO2009022236A2 (en) | 2007-08-16 | 2009-02-19 | Tripep Ab | Immunogen platform |
ITUD20080055A1 (it) * | 2008-03-13 | 2009-09-14 | Transactiva S R L | Procedimento per la produzione di una proteina umana in pianta, in particolare un enzima lisosomiale umano ricombinante in endosperma di cereali |
US10485879B2 (en) | 2008-04-15 | 2019-11-26 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues |
NZ592977A (en) | 2008-12-09 | 2013-01-25 | Pfizer Vaccines Llc | IgE CH3 PEPTIDE VACCINE |
NZ618391A (en) | 2009-07-30 | 2015-07-31 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
KR101660578B1 (ko) | 2009-09-03 | 2016-09-27 | 화이자 백신스 엘엘씨 | Pcsk9 백신 |
EP2575868A1 (en) | 2010-06-07 | 2013-04-10 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
US20120328605A1 (en) * | 2010-10-27 | 2012-12-27 | Daniel Larocque | Compositions and uses |
WO2012082803A2 (en) * | 2010-12-13 | 2012-06-21 | Cel-Sci Corporation | Method for inducing an immune response against avian, swine, spanish, h1n1, h5n9 influenza viruses and formulations thereof |
PT2672992T (pt) | 2011-02-11 | 2020-07-27 | Univ Pennsylvania | Molécula de ácidos nucleicos codificando proteína nuclear do vírus da hepatite b e vacina compreendendo a mesma |
WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
EP2698164B1 (en) | 2011-04-15 | 2018-04-04 | Osaka University | Dna vaccine |
WO2012162564A1 (en) | 2011-05-25 | 2012-11-29 | Cel-Sci Corporation | Method for inducing an immune response and formulations thereof |
SI2717898T1 (sl) * | 2011-06-10 | 2019-07-31 | Bioverativ Therapeutics Inc. | Spojine prokoagulantov in metode za njihovo uporabo |
WO2014034735A1 (ja) | 2012-08-31 | 2014-03-06 | 国立大学法人 大阪大学 | Vegf及び/又はアンギオポエチン-2の特異的エピトープを含むdnaワクチン |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
CN111925423B (zh) * | 2014-11-07 | 2022-08-19 | 普莱柯生物工程股份有限公司 | 一种抗o型口蹄疫的疫苗组合物及其制备方法和应用 |
WO2019008001A1 (en) | 2017-07-04 | 2019-01-10 | Curevac Ag | NEW NUCLEIC ACID MOLECULES |
JP2021501572A (ja) | 2017-10-19 | 2021-01-21 | キュアバック アーゲー | 新規な人工核酸分子 |
TW202039534A (zh) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
CA3155202A1 (en) | 2019-10-23 | 2021-04-29 | Arthur M. Krieg | Synthetic rig-i-like receptor agonists |
CN113943075A (zh) * | 2020-07-15 | 2022-01-18 | 湖南怡田美农业科技有限公司 | 一种剑麻皂素提取后的污染处理方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4767842A (en) * | 1973-05-07 | 1988-08-30 | The Ohio State University | Antigenic modification of polypeptides |
US5614194A (en) * | 1981-02-12 | 1997-03-25 | New York University | Protective peptide antigen |
US4888170A (en) * | 1981-10-22 | 1989-12-19 | Research Corporation | Vaccines obtained from antigenic gene products of recombinant genes |
US4643992A (en) * | 1982-11-09 | 1987-02-17 | Scripps Clinic And Research Foundation | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives |
US4539205A (en) * | 1982-11-09 | 1985-09-03 | Scripps Clinic And Research Foundation | Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives |
US4987237A (en) * | 1983-08-26 | 1991-01-22 | Ribi Immunochem Research, Inc. | Derivatives of monophosphoryl lipid A |
US5093318A (en) * | 1983-11-01 | 1992-03-03 | Scripps Clinic And Research Foundation | Immunostimulating guanosine derivatives and their pharmaceutical compositions |
US5011828A (en) * | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
US4882145A (en) * | 1986-12-09 | 1989-11-21 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US4818527A (en) * | 1986-12-09 | 1989-04-04 | Scripps Clinic And Research Foundation | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US5143726A (en) * | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US4886782A (en) * | 1987-02-26 | 1989-12-12 | The United States Of America As Represented By The Department Of Health And Human Services | Malarial immunogen |
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5387744A (en) * | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
EP0433372B1 (en) * | 1988-09-06 | 2002-06-12 | Washington University | Oral immunization by transgenic plants |
US5023179A (en) * | 1988-11-14 | 1991-06-11 | Eric Lam | Promoter enhancer element for gene expression in plant roots |
US5110732A (en) * | 1989-03-14 | 1992-05-05 | The Rockefeller University | Selective gene expression in plants |
NZ235315A (en) * | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
DE69132769T2 (de) * | 1990-03-02 | 2002-04-18 | Bp Corp North America Inc | Biosynthese von carotinoiden in genetisch hergestellten wirtszellen |
US5618988A (en) * | 1990-03-02 | 1997-04-08 | Amoco Corporation | Enhanced carotenoid accumulation in storage organs of genetically engineered plants |
US5709879A (en) * | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
US5928902A (en) * | 1992-02-27 | 1999-07-27 | Smithkline Beecham Biologicals (S.A.) | Hybrid protein between CS from plasmodium and HBsAg |
US5297441A (en) * | 1992-08-14 | 1994-03-29 | The Boeing Company | Apparatus for supporting a test specimen for compression testing |
US6024961A (en) * | 1997-11-14 | 2000-02-15 | Washington University | Recombinant avirulent immunogenic S typhi having rpos positive phenotype |
ATE215385T1 (de) * | 1997-12-16 | 2002-04-15 | Chiron Corp | Verwendung von mikropartikeln mit submikron öl/wasser emulsionen |
AU767144B2 (en) * | 1998-02-12 | 2003-10-30 | Apovia, Inc. | Strategically modified hepatitis B core proteins and their derivatives |
US5990085A (en) * | 1998-05-04 | 1999-11-23 | Michigan State University | Inhibin-HBc fusion protein |
WO2001085208A2 (en) * | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
-
2001
- 2001-08-15 US US09/930,915 patent/US20030138769A1/en not_active Abandoned
- 2001-08-16 KR KR10-2003-7002259A patent/KR20030084887A/ko active Search and Examination
- 2001-08-16 JP JP2002519606A patent/JP2005517380A/ja active Pending
- 2001-08-16 AP APAP/P/2003/002752A patent/AP2003002752A0/en unknown
- 2001-08-16 BR BR0113307-1A patent/BR0113307A/pt not_active IP Right Cessation
- 2001-08-16 EP EP01964615A patent/EP1333857A4/en not_active Withdrawn
- 2001-08-16 CA CA002420037A patent/CA2420037A1/en not_active Abandoned
- 2001-08-16 WO PCT/US2001/041759 patent/WO2002014478A2/en active Application Filing
- 2001-08-16 AU AU2001285452A patent/AU2001285452B2/en not_active Ceased
- 2001-08-16 EA EA200300270A patent/EA006207B1/ru not_active IP Right Cessation
- 2001-08-16 AU AU8545201A patent/AU8545201A/xx active Pending
- 2001-08-16 OA OA1200300045A patent/OA12366A/en unknown
- 2001-08-16 MX MXPA03001338A patent/MXPA03001338A/es not_active Application Discontinuation
-
2004
- 2004-03-22 US US10/806,006 patent/US20040152876A1/en not_active Abandoned
- 2004-03-22 US US10/805,913 patent/US20040156864A1/en not_active Abandoned
-
2012
- 2012-04-09 JP JP2012088679A patent/JP2012139237A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU8545201A (en) | 2002-02-25 |
KR20030084887A (ko) | 2003-11-01 |
JP2005517380A (ja) | 2005-06-16 |
AP2003002752A0 (en) | 2003-06-30 |
EP1333857A4 (en) | 2006-02-22 |
WO2002014478A3 (en) | 2003-06-05 |
EA006207B1 (ru) | 2005-10-27 |
US20040152876A1 (en) | 2004-08-05 |
JP2012139237A (ja) | 2012-07-26 |
US20040156864A1 (en) | 2004-08-12 |
BR0113307A (pt) | 2005-06-28 |
US20030138769A1 (en) | 2003-07-24 |
WO2002014478A2 (en) | 2002-02-21 |
AU2001285452B2 (en) | 2006-11-02 |
CA2420037A1 (en) | 2002-02-21 |
EA200300270A1 (ru) | 2004-04-29 |
OA12366A (en) | 2006-05-17 |
EP1333857A2 (en) | 2003-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03001338A (es) | Particulas quimericas 11bc inmunogenicas con mayor estabilidad. | |
EG24742A (en) | Vaccine composition. | |
EP1346724A4 (en) | REMEDIES FOR HEPATITIS C | |
AP2003002827A0 (en) | Black tea manufacture. | |
HUP0402067A3 (en) | Vaccines | |
ZA200007669B (en) | Insert. | |
GB0010315D0 (en) | Black tea manufacture | |
GB0024200D0 (en) | Component vaccine | |
HK1044363A1 (en) | Headlight. | |
MXPA01007826A (es) | Diferencial que proporciona torsion, con trabado completo. | |
EP1346283A4 (en) | VIVA | |
IL153879A0 (en) | Modified virus | |
EP1337440A4 (en) | DOCUMENT ENVELOPE | |
PL351348A1 (en) | Self-boostering synchroniser | |
MXPA03001951A (es) | Pirroliminas y pirazoliminas fusionadas substituidas. | |
PL360539A1 (en) | Synchronizer | |
GB0001475D0 (en) | Virus strains | |
GB0001776D0 (en) | Mouse | |
HK1039441A1 (en) | Baby back-carrier. | |
MXPA03004040A (es) | Composiciones hidroliticamente inestables. | |
HK1040248A1 (en) | Process for the preparation of isoindoline. | |
EP1290230A4 (en) | HEPATITIS C VIRUS CONJUGATE | |
GB0026361D0 (en) | Synchroniser | |
AU2003213194A8 (en) | Immunogenic avian hbc chimer particles having enhanced stability | |
GB0008322D0 (en) | Stroller |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |